Regula Deurloo

1.9k total citations · 1 hit paper
12 papers, 947 citations indexed

About

Regula Deurloo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Regula Deurloo has authored 12 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Regula Deurloo's work include Cancer Immunotherapy and Biomarkers (8 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). Regula Deurloo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (4 papers). Regula Deurloo collaborates with scholars based in Switzerland, Germany and France. Regula Deurloo's co-authors include Herbert I. Hurwitz, Robert L. Coleman, Olivier Chinot, Josep Garcia, Alan B. Sandler, David Miles, Giuseppe Viale, Sunil Badve, Jorge S. Reis‐Filho and Corrado D’Arrigo and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Regula Deurloo

12 papers receiving 941 citations

Hit Papers

Bevacizumab (Avastin®) in cancer treatment: A review of 1... 2020 2026 2022 2024 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
    2020 780 citations Josep Garcia, Herbert I. Hurwitz et al. Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Regula Deurloo Switzerland 5 468 316 222 215 153 12 947
Qingfang Li China 17 336 0.7× 437 1.4× 235 1.1× 222 1.0× 175 1.1× 37 1.0k
Carlos A. Castañeda Peru 15 461 1.0× 286 0.9× 250 1.1× 167 0.8× 162 1.1× 66 893
Takafumi Koyama Japan 19 447 1.0× 293 0.9× 144 0.6× 168 0.8× 136 0.9× 87 871
Teresa Di Desidero Italy 24 542 1.2× 421 1.3× 200 0.9× 253 1.2× 74 0.5× 52 1.1k
Susanna V. Ulahannan United States 17 524 1.1× 324 1.0× 168 0.8× 192 0.9× 197 1.3× 89 1.1k
Lian Xu China 17 449 1.0× 475 1.5× 316 1.4× 314 1.5× 145 0.9× 40 1.1k
Christopher Ruel United States 18 536 1.1× 468 1.5× 131 0.6× 309 1.4× 154 1.0× 47 1.0k
Cuiju Tang China 14 340 0.7× 382 1.2× 178 0.8× 240 1.1× 96 0.6× 47 853
Erwan Pencreach France 17 350 0.7× 323 1.0× 248 1.1× 200 0.9× 82 0.5× 35 797
Takahiro Kogawa Japan 19 771 1.6× 334 1.1× 338 1.5× 244 1.1× 115 0.8× 86 1.2k

Countries citing papers authored by Regula Deurloo

Since Specialization
Citations

This map shows the geographic impact of Regula Deurloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Regula Deurloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Regula Deurloo more than expected).

Fields of papers citing papers by Regula Deurloo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Regula Deurloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Regula Deurloo. The network helps show where Regula Deurloo may publish in the future.

Co-authorship network of co-authors of Regula Deurloo

This figure shows the co-authorship network connecting the top 25 collaborators of Regula Deurloo. A scholar is included among the top collaborators of Regula Deurloo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Regula Deurloo. Regula Deurloo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Vries, Elisabeth G.E. de, Josef Rüschoff, Martijn P. Lolkema, et al.. (2023). Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Cancer Medicine. 12(11). 12071–12083. 40 indexed citations
3.
4.
Molinero, Luciana, Xiangnan Guan, Regula Deurloo, et al.. (2022). Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).. Journal of Clinical Oncology. 40(16_suppl). 1083–1083. 1 indexed citations
5.
Harbeck, Nadia, Raquel von Schumann, Ronald Kates, et al.. (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers. 13(19). 4884–4884. 10 indexed citations
6.
7.
Badve, Sunil, Frédérique Penault‐Llorca, Jorge S. Reis‐Filho, et al.. (2021). Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. JNCI Journal of the National Cancer Institute. 114(5). 664–675. 45 indexed citations
8.
Garcia, Josep, Herbert I. Hurwitz, Alan B. Sandler, et al.. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 86. 102017–102017. 780 indexed citations breakdown →
9.
Cortés, Javier, Fabrice André, Anthony Gonçalvès, et al.. (2019). Impassion132 Phase Iii Trial: Atezolizumab And Chemotherapy In Early Relapsing Metastatic Triple-Negative Breast Cancer. Future Oncology. 15(17). 1951–1961. 57 indexed citations
10.
Harbeck, Nadia, Ulrike Nitz, Matthias Christgen, et al.. (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.. Journal of Clinical Oncology. 36(15_suppl). 572–572. 1 indexed citations
11.
12.
Oza, Amit M., Ірина Давиденко, Jacob Korach, et al.. (2015). 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). European Journal of Cancer. 51. S532–S532. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qingfang Li Breakdown of academic impact, for papers by Carlos A. Castañeda Breakdown of academic impact, for papers by Takafumi Koyama Breakdown of academic impact, for papers by Teresa Di Desidero Breakdown of academic impact, for papers by Susanna V. Ulahannan Breakdown of academic impact, for papers by Lian Xu Breakdown of academic impact, for papers by Christopher Ruel Breakdown of academic impact, for papers by Cuiju Tang Breakdown of academic impact, for papers by Erwan Pencreach Breakdown of academic impact, for papers by Takahiro Kogawa
Rankless by CCL
2026